183. Centers for Disease Control and Prevention. Cancer Survivorship—
United States, 1971-2001. MMWR Morb Mortal Wkly Rep
184. American Cancer Society. Cancer Facts and Figures 2014. Atlanta
(GA): American Cancer Society; 2014.
185. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg
K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the
treatment of carcinoid syndrome. J Clin Oncol 2017;35: 14–23.
186. Trusson D, Pilnick A. The role of hair loss in cancer identity:
perceptions of chemotherapy-induced alopecia among women
treated for early-stage breast cancer or ductal carcinoma in situ.
Cancer Nurs 2017;40:E9–16.
187. Nangia J, Wang T, Osborne CK, Niravath P, Otte K, Papish S, et al.
Effect of a scalp cooling device on alopecia in women undergoing
chemotherapy for breast cancer. JAMA 2017;317:596–605.
188. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between
patient-reported symptoms and their documentation in the medical
record. Am J Manag Care 2008;14:530– 9.
189. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al.
Overall survival results of a trial assessing patient-reported outcomes
for symptom monitoring during routine cancer treatment. JAMA
190. Arrieta O, Angulo LP, Nunez-Valencia C, Dorantes-Gallareta Y,
Macedo EO, Martinez-Lopez D, et al. Association of depression
and anxiety on quality of life, treatment adherence, and prognosis
in patients with advanced non-small cell lung cancer. Ann Surg
191. Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, et al.
Psychiatric morbidity and impact on hospital length of stay among
hematologic cancer patients receiving stem-cell transplantation. J
Clin Oncol 2002;20:1907–17.
192. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A,
Goldhirsch A. Depression and degree of acceptance of adjuvant
cytotoxic drugs. Lancet 2000;356:1326–7.
193. Brown K W, Levy AR, Rosberger Z, Edgar L. Psychological distress
and cancer survival: a follow-up 10 years after diagnosis. Psychosom
194. Dieng M, Butow PN, Costa DS, Morton RL, Menzies SW,
Mireskandari S, et al. Psychoeducational intervention to reduce
fear of cancer recurrence in people at high risk of developing another
primary melanoma: results of a randomized controlled trial. J Clin
195. Lichtenthal WG, Corner GW, Slivjak ET, Roberts KE, Li Y, Breitbart W,
et al. A pilot randomized controlled trial of cognitive bias modification
to reduce fear of breast cancer recurrence. Cancer 2017;123:1424–33.
196. Breitbart W, Rosenfeld B, Pessin H, Applebaum A, Kulikowski
J, Lichtenthal WG. Meaning-centered group psychotherapy: an
effective intervention for improving psychological well-being in
patients with advanced cancer. J Clin Oncol 2015;33:749–54.
197. Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, et
al. Evaluation of a web-based cognitive rehabilitation program in
cancer survivors reporting cognitive symptoms after chemotherapy.
J Clin Oncol 2017;35:217–25.
198. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et
al. Rapid and sustained symptom reduction following psilocybin
treatment for anxiety and depression in patients with life-threatening
cancer: a randomized controlled trial. J Psychopharmacol
199. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA,
Richards BD, et al. Psilocybin produces substantial and sustained
decreases in depression and anxiety in patients with life-threatening
cancer: A randomized double-blind trial. J Psychopharmacol
200. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and correlates
of smoking and cessation-related behavior among survivors of ten
cancers: findings from a nationwide survey nine years after diagnosis.
Cancer Epidemiol Biomarkers Prev 2014;23:1783–92.
201. U.S. Department of Health and Human Services. The Surgeon
General’s call to action to prevent skin cancer. Washington (DC):
U.S. Dept of Health and Human Services, Office of the Surgeon
202. Vogel RI, Strayer LG, Engelman L, Nelson HH, Blaes AH, Anderson
KE, et al. Sun exposure and protection behaviors among long-term
melanoma survivors and population controls. Cancer Epidemiol
Biomarkers Prev 2017;26:607–13.
203. Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical
activity and cancer outcomes: a precision medicine approach. Clin
Cancer Res 2016;22:4766–75.
204. Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K,
Friedenreich CM, et al. Effects of exercise during adjuvant
chemotherapy on breast cancer outcomes. Med Sci Sports Exerc
205. Courneya KS, Vardy JL, O’Callaghan CJ, Friedenreich CM, Campbell
KL, Prapavessis H, et al. Effects of a structured exercise program
on physical activity and fitness in colon cancer survivors: one year
feasibility results from the CHALLENGE trial. Cancer Epidemiol
Biomarkers Prev 2016;25:969–77.
206. Alix-Panabières C, Pantel K. Clinical prospects of liquid biopsies.
Nat Biomed Eng 2017;1: 65.
207. The Clinical Cancer Genome Task Team of the Global Alliance for
Genomics and Health. Sharing clinical and genomic data on cancer
— the need for global solutions. N Engl J Med 2017;376:2006–9.
208. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers
JM, Flowers CR, et al. Charting the future of cancer health disparities
research: a position statement from the American Association for
Cancer Research, the American Cancer Society, the American
Society of Clinical Oncology, and the National Cancer Institute.
Cancer Res 2017 Jul 24. [Epub ahead of print].
209. Unger JM, LeBlanc M, Blanke CD. The effect of positive SWOG
treatment trials on survival of patients with cancer in the US
population. JAMA Oncol 2017 Jun 5. [Epub ahead of print].
210. Biden JJ, et al. Report of the Cancer Moonshot Task Force. 2016; 1–38.
Available from: https://obamawhitehouse.archives.gov/sites/default/
211. Menikoff J, Kaneshiro J, Pritchard I. The common rule, updated.
N Engl J Med 2017;376:613–5.